Arecor Therapeutics plc
("Arecor" or the "Company")
NOTICE OF RESULTS
Cambridge, UK, 10 April 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, will announce its audited final results for the year ended 31 December 2024 on Tuesday 22 April 2025.
Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host an in-person briefing for analysts on the day of the results. There will also be a live webcast and conference call with a Q&A session.
For more details or to attend the briefing, please contact arecor@icrhealthcare.com
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
www.arecor.com |
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
David Ellam, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
Singer Capital Markets Advisory LLP (NOMAD and Broker) |
|
|
Phil Davies, Sam Butcher |
Tel: +44 (0) 20 7496 3000 |
|
ICR Healthcare |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@icrhealthcare.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com